Theolytics to raise £5 million Series A round led by co-led by Epidarex Capital and Taiho Ventures LLC

Theolytics, an Oxford, UK-based developer of cancer therapies, raised £5 million in Series A funding.

The money was raised from investors co-led by Epidarex Capital and Taiho Ventures, with participation from Oxford Sciences Innovation. Henning Steinhagen, Venture Partner at Epidarex, and Sakae Asanuma, President at Taiho Ventures will join as new board members.

The financing will be used to progress the company’s pipeline of candidates towards human clinical trials.

Theolytics, led by CEO Charlotte Casebourne, is focused on creating a step-change in the oncolytic viral therapy field, by using its phenotypic screening platform to discover and develop highly efficacious, targeted candidates, suitable for intravenous delivery and optimised for a chosen cancer patient population.